CVS Caremark’s Q2 growth prompted by Walgreens-ESI stalemate
WOONSOCKET, R.I. — The stalemate between Walgreens and Express Scripts may have come to an end, but CVS Caremark remains optimistic and has developed a multifaceted plan to help it retain a significant number of the prescriptions gained from the impasse, CVS Caremark president and CEO Larry Merlo told analysts during Tuesday morning’s second-quarter conference call.
Meanwhile, CVS Caremark’s solid second-quarter performance and outlook has prompted the company to raise yet narrow its guidance for the year. CVS Caremark now expects to deliver adjusted earnings per share of $3.32 to $3.38 for the full year 2012, up from its previous guidance of $3.23 to $3.33.
“The retail business continued to take advantage of the unprecedented opportunity presented to us by the stalemate between Walgreens and Express Scripts. This resulted in significant market share growth in the quarter and, as anticipated, we realized about a 3.5-cent benefit in Q2 from the impasse,” Merlo told analysts. “Now, with the recent news that Walgreens will re-enter the broadest Express Scripts network this Sept. 15, we estimate that we will generate an additional benefit of approximately 5 cents per share in the second half of the year.”
That estimate assumes that, in the fourth quarter, CVS Caremark retains at least 50% of the prescription volumes gained from the impasse. In addition, the 5-cents-per-share additional benefit is net of estimated investments the company will make to maximize retention.
For the quarter ended June 30, pharmacy same-store sales rose 7.2%, compared with the year-ago period and included a significant benefit associated with Walgreens not being a part of the Express Scripts pharmacy provider network during the quarter. In addition, pharmacy same-store prescription volumes rose 7.7% when 90-day scripts are counted as one script. When converting 90-day scripts into three scripts, the same-store prescription volumes rose 9.8% during the quarter.
It is estimated that the stalemate added 410 to 430 basis points to its pharmacy same-store sales and 400 to 430 basis points to its script comps during the quarter, equating to roughly 6.5 million to 7 million scripts.
“In light of the timing of the recently announced settlement by our competitors we expect to retain a vast majority of the scripts we gained through the third quarter and to retain at least 50% in the fourth quarter,” Merlo said. “Many of you have asked how we expect to accomplish that level of retention and, while it obviously wouldn’t make sense to discuss our specific retention strategies for competitive reasons, I can assure you that we have a highly detailed, multifaceted plan in place to achieve our goals.”
According to Merlo, this multipronged plan involves customer outreach, in-store touch points, advertising and promotions. The plan is based on “sophisticated analytics and it makes economic sense,” Merlo said.
“So, we are very confident that we will retain a significant portion of that business,” Merlo told analysts.
2013 selling season “well under way”
With the 2013 selling season well under way, Merlo said he is pleased with the overall success in the season, thus far. With most health plans and larger employers having made their decisions for Jan. 1, the focus is now on mid-year 2013 opportunities, plus a significant number of opportunities for 2014.
To date, gross wins have totaled $3.5 billion, resulting in net-new business of $640 million to date, on a 2013 impact basis.
Merlo also told analysts that the company is seeing increased interest in narrower networks. He added that, in fact, clients representing about 20% of the new revenue signed for 2013 have adopted a limited pharmacy network, and that excludes those clients that have signed on for the Maintenance Choice program.
“So while we’re not seeing a watershed change in the adoption of limited networks, it is clearly a factor in the selling season and it will continue to be on the table as a cost-savings opportunity for clients,” Merlo told analysts.
Merlo also told analysts that the company continues to see strong interest in its proprietary programs — which CVS Caremark refers to as its integration sweet spots — such as Maintenance Choice and Pharmacy Choice, and also experienced strong double-digit growth in specialty pharmacy. In fact, specialty pharmacy revenues rose 44% during the quarter.
Revenues for the pharmacy services segment rose 28.2% to $18.4 billion, driven largely by new clients, drug cost inflation and new activity resulting from its acquisition of the Medicare prescription drug plan of Universal American in April 2011.
Meanwhile, retail revenues rose 6.9% to $15.8 billion. Same-store sales rose 5.6%, as front-end same-store sales increased 2.3% during the quarter.
MinuteClinic posted a 17% boost in second-quarter revenues and ended the quarter with 584 clinics.
Income from continuing operations attributable to CVS Caremark rose $153 million to $967 million. Adjusted EPS from continuing operations attributable to CVS Caremark were 81 cents per share compared with 65 cents per share in the year-ago period.
Walmart Foundation empowers women with new partnerships
BENTONVILLE, Ark. — The Walmart Foundation, alongside six women’s foundations — The Washington Area Women’s Foundation, The New York Women’s Foundation, Women’s Fund of Mississippi, Women’s Foundation of Minnesota, Women’s Foundation for a Greater Memphis and the Women’s Funding Network — has launched the Partnership for Women’s Prosperity.
The new national partnership intends to help economically vulnerable women gain financial and economic security through education, job training and employment opportunities. The Walmart Foundation has provided $3.35 million in grants to the Partnership for Women’s Prosperity to initiate efforts and assist nearly 5,000 women and girls in 16 communities across the United States.
"We are thankful to the Walmart Foundation for recognizing the impact that women’s funds are having on communities and the innovative and effective ways in which they’re providing resources that enable economically vulnerable women to overcome barriers and reach their full potential," said Nicola Goren, president and CEO of the Washington Area Women’s Foundation. "By working together as a collective force, we have the potential to transform the role of economically disadvantaged women across the United States."
The Walmart Foundation worked closely with the Partnership for Women’s Prosperity to establish goals and fund programs that best serve women in their local communities. Specifically, the grants will provide programs that help women:
Advance careers: Offer greater job training and career services to help women find and secure stable jobs and ensure access to affordable child care options;
Increase financial literacy: Equip women with the right tools to help them build their net worth by reducing debt and accumulating savings;
Access education: Expand access to educational opportunities including GED, English as a Second Language, and post-secondary courses to increase knowledge that will help secure job; and
Build leadership skills: Empower young women and girls with the ability to raise grades, increase graduation rates and improve access to higher education and stable jobs.
"These dedicated partners are working on the ground community by community to help women expand their knowledge and build essential skills that will improve their lives," said Sylvia Mathews Burwell, president of the Walmart Foundation. "We know that outside of work, women spend their time, money and energy caring for their families and communities, so investing in women today will help build a greater future for our nation."
This announcement is part of Walmart’s Global Women’s Economic Empowerment Initiative launched in September 2011 that aims to help 200,000 U.S. women from low-income households gain job skills, access to higher education and achieve economic security.
Lilly announces osteoporosis drug study results
INDIANAPOLIS — A biotech drug made by Eli Lilly for osteoporosis appeared no more or less effective than a pharmaceutical drug available as a generic in treating women with related bone fractures, but was more effective in some other measures, according to results of a late-stage clinical trial released Tuesday.
Lilly released results of a phase-3 study of Forteo (teriparatide [rDNA origin]) in postmenopausal women with osteoporotic vertebral fractures that compared the drug with risedronate, originally marketed by Warner Chilcott under the brand name Actonel. The study found no difference between Forteo and risedronate in the ability to reduce the worst back pain by 30% after six months, but patients using Forteo showed greater increases in bone mineral density and fewer new vertebral fractures. Results of the study are in the August issue of the journal Osteoporosis International.
"With many available options to treat osteoporosis, this study is important because it compares two established osteoporosis medicines in a direct, head-to-head design," said Peyman Hadji, Philipps-University of Marburg endocrinology, osteoporosis and reproductive medicine department head and lead study investigator.